Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Gan & Lee Plans $226 Million China IPO

publication date: Jun 16, 2016
Gan & Lee, China's largest domestic maker of insulin products, plans to stage a $226 million IPO on a China exchange. China's security regulator has approved Gan & Lee's application. Founded in 1998, Gan & Lee produced China's first recombinant insulin, Gansulin®, which was followed in 2001 by the short-acting insulin analog Prandilin® (lispro), and then China's first long-acting insulin analog Basalin® (glargine) in 2002. Gan & Lee is the only China company to market all three generations of insulin-type products. Gan & Lee is headquartered in Beijing. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital